<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00326482</url>
  </required_header>
  <id_info>
    <org_study_id>060153</org_study_id>
    <secondary_id>06-I-0153</secondary_id>
    <nct_id>NCT00326482</nct_id>
  </id_info>
  <brief_title>Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy</brief_title>
  <official_title>A Pilot Study of Hepatic Fibrosis in HIV/AIDS Patients With Chronically Elevated Transaminases on Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will provide a basis for research on the impact of liver injury caused by&#xD;
      antiretroviral therapy in HIV-infected patients. Elevated liver enzymes called AST and ALT&#xD;
      are common in HIV-infected patients taking antiretroviral medications and can indicate liver&#xD;
      damage. Although there are a number of possible causes for these elevations, such as&#xD;
      infections with a hepatitis virus, antiretroviral medications alone can lead to the&#xD;
      elevations. The study will focus particularly on evidence of liver fibrosis, which is a sign&#xD;
      of progressive liver damage.&#xD;
&#xD;
      HIV-infected patients 18 and older who 1) have been taking combination antiretroviral therapy&#xD;
      for at least 12 months and have been on a stable regimen for at least 3 months, and 2) have&#xD;
      had elevated AST or ALT levels for at least 6 months may be eligible for this study. Patients&#xD;
      who have had liver biopsies performed in the past may be eligible for participation.&#xD;
&#xD;
      Participants undergo the following tests and procedures over a 12-month period:&#xD;
&#xD;
        -  Oral glucose tolerance test: The patient drinks a glucose (sugar) drink. Blood samples&#xD;
           are then drawn over 2 hours through an intravenous (IV) line in the patient's arm. This&#xD;
           test measures how high the patient's blood sugar and insulin levels rise after drinking&#xD;
           a standard glucose load.&#xD;
&#xD;
        -  Transient elastography: This ultrasound test uses vibration (sound waves) to measure&#xD;
           liver stiffness (fibrosis). Vibrations move faster through a fibrotic liver.&#xD;
&#xD;
        -  Triple-phase CT scan and single slice CT scan of L4-5: Patients fast for 4 hours before&#xD;
           the CT scan. A contrast material is injected through a catheter placed in an arm vein to&#xD;
           improve the visibility of the liver in the specialized X-ray images obtained in the CT&#xD;
           scanner.&#xD;
&#xD;
        -  Liver biopsy: This test removes a small sample of liver tissue for microscopic&#xD;
           examination, particularly for evidence of fibrosis. The skin over the biopsy site is&#xD;
           numbed and a needle is passed through the skin and rapidly in and out of the liver.&#xD;
           Patients may be given a sedative for the procedure.&#xD;
&#xD;
        -  Follow-up visits. Patients return for follow-up visits 1 to 4 weeks after the liver&#xD;
           biopsy and three more times over the course of the study for a medical history, physical&#xD;
           examination and blood tests.&#xD;
&#xD;
      Patients may participate in an additional 4-year follow-up, during which they have visits&#xD;
      every 3-12 months and are offered the opportunity to repeat the biopsy no sooner than 1 year&#xD;
      after the first biopsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At present, there are no clear guidelines as to when antiretroviral therapy for human&#xD;
      immunodeficiency virus (HIV) infection should be stopped in the setting of elevated liver&#xD;
      enzymes. In large part, this is due to a limited understanding of the natural history of&#xD;
      antiretroviral-related hepatotoxicity. Although several antiretrovirals have been reported to&#xD;
      cause fatal acute hepatitis, more often they cause an asymptomatic elevation in transaminase&#xD;
      levels, the optimal management of which is uncertain. This pilot study seeks to create a&#xD;
      foundation for research on the impact of antiretroviral-induced liver injury by providing an&#xD;
      estimate of the prevalence of hepatic fibrosis in a cohort of sixty HIV-infected patients who&#xD;
      have chronically elevated transaminases while on antiretroviral therapy in the absence of&#xD;
      chronic hepatitis B (HBV) or C (HCV) coinfection. Liver biopsy specimens will be evaluated&#xD;
      for fibrosis by microscopic examination, the current gold standard for assessing the nature&#xD;
      and severity of liver disease.[1] The presence of fibrosis, as well as other histopathology,&#xD;
      will be described using a validated scoring system. Primarily, this will be a crosssectional&#xD;
      study, but subjects will be offered the opportunity to participate in an extended follow-up&#xD;
      period and undergo another liver biopsy. Individuals will not be excluded on the basis of&#xD;
      alcohol abuse, insulin resistance, or lipodystrophy, but data will be collected on these&#xD;
      potentially confounding variables. Noninvasive measures, such as transient elastography (an&#xD;
      ultrasonic technique), will be assessed for their ability to predict fibrosis in this&#xD;
      population. Correlations will also be sought with laboratory markers of fibrosis. The&#xD;
      identification of fibrosis (and its precursors) in association with antiretroviral therapy&#xD;
      may be very clinically relevant as it may slowly regress with cessation of the causal&#xD;
      agent(s). If the causal agent is continued, however, cirrhosis may develop, the reversal of&#xD;
      which is thought to be rare.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 31, 2006</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of hepatic fibrosis on liver biopsy as measured histologically by stage</measure>
    <time_frame>At study entry, potential for repeat liver biopsy staging during longitudinal follow-up</time_frame>
    <description>Liver Biopsy Scoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver biopsy evidence of hepatic steatosis as measured by degree (0 to 4), character and location</measure>
    <time_frame>At study entry, potential for repeat liver biopsy staging during longitudinal follow-up</time_frame>
    <description>Liver Biopsy Scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver biopsy evidence of hepatic inflammation by type and severity</measure>
    <time_frame>At study entry, potential for repeat liver biopsy staging during longitudinal follow-up</time_frame>
    <description>Liver Biopsy Scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between histopathologic findings on liver biopsy and clinical, laboratory and radiologic parameters</measure>
    <time_frame>At study entry, longitudinally</time_frame>
    <description>Liver Biopsy Scoring</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">127</enrollment>
  <condition>Liver Fibrosis</condition>
  <condition>Steatohepatitis</condition>
  <condition>Elevated Transaminases</condition>
  <arm_group>
    <arm_group_label>Prior Liver Biopsy</arm_group_label>
    <description>HIV+ historical liver biopsy history</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective Liver Biopsy with ARV</arm_group_label>
    <description>HIV+ taking c/ARV medications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective Liver Biopsy without ARV</arm_group_label>
    <description>HIV+ not taking c/ARV medications</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients with chronically elevated transaminases while on c/ARV medications or&#xD;
        not on c /ARV medications that agree to research procedures that investigate the prevalence&#xD;
        of hepatic fibrosis in the absence of hepatitis B or C co-infection@@@&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Age 18 years or older.&#xD;
&#xD;
        Ability to understand and willingness to provide written informed consent.&#xD;
&#xD;
        Willingness to undergo liver biopsy.&#xD;
&#xD;
        Willingness to comply with study requirements and procedures including storage of blood and&#xD;
        liver tissue samples for use in future studies of HIV, AIDS, immune function, hepatic&#xD;
        diseases, or other related diseases.&#xD;
&#xD;
        Established HIV diagnosis (documentation of HIV-1 infection by licensed ELISA testing and&#xD;
        confirmed by Western Blot).&#xD;
&#xD;
        For the antiretroviral cohort on combination antiretroviral therapy for at least 12 months&#xD;
        with stable regimen for at least 3 months prior to enrollment.&#xD;
&#xD;
        Chronically elevated transaminases for at least 6 months documented by an elevated AST&#xD;
        and/or ALT on the following 3 occasions within the 12 months prior to enrollment:&#xD;
&#xD;
          1. Screening;&#xD;
&#xD;
          2. Less than 6 months (24 weeks) prior to enrollment (distinct from screening);&#xD;
&#xD;
          3. More than 6 months prior to enrollment.&#xD;
&#xD;
             Note: Occasions must be at least 8 weeks apart.&#xD;
&#xD;
             Specific screening lab criteria:&#xD;
&#xD;
               -  AST and/or ALT greater than upper limit of normal;&#xD;
&#xD;
               -  Absolute neutrophil count greater than 750/mm(3);&#xD;
&#xD;
               -  PT/PTT within normal range;&#xD;
&#xD;
               -  Platelets greater than 50,000/uL;&#xD;
&#xD;
               -  Hemoglobin greater than or equal to 10 mg/dL;&#xD;
&#xD;
               -  Creatinine less than or equal to 2.0 mg/dL;&#xD;
&#xD;
               -  Negative serum or urine pregnancy test for females of childbearing potential.&#xD;
&#xD;
             Willingness to avoid medications that contain aspirin for 7 days PRIOR to liver biopsy&#xD;
             and nonsteroidal anti-inflammatory drugs for 3 days PRIOR to liver biopsy.&#xD;
&#xD;
             Willingness to avoid medications that contain aspirin for a week AFTER liver biopsy.&#xD;
&#xD;
             Willingness to avoid other medications or herbal supplements (e.g., gingko biloba)&#xD;
             which may increase the risk of bleeding before and after liver biopsy, as directed by&#xD;
             the study team.&#xD;
&#xD;
             Willingness to restrict activity for 72 hours after liver biopsy.&#xD;
&#xD;
             Have a primary care physician.&#xD;
&#xD;
             HIV monoinfected individuals who have had a previous liver biopsy to evaluate&#xD;
             chronically elevated transaminases on antiretroviral therapy or for another indication&#xD;
             may be allowed to enroll in the study for the purposes of obtaining additional&#xD;
             information on predictors of liver disease and to observe the natural history. In such&#xD;
             instances, investigators will attempt to access this tissue for review.&#xD;
&#xD;
             EXCLUSION CRITERIA:&#xD;
&#xD;
             Chronic hepatitis B infection (defined as positive HBsAg or hepatitis B viral load&#xD;
             greater than 10,000 copies/ml).&#xD;
&#xD;
             Hepatitis C infection (defined as positive HCV viral load) or history of treatment for&#xD;
             chronic hepatitis C.&#xD;
&#xD;
             Acute Hepatitis A infection (defined as HAV IgM positive).&#xD;
&#xD;
             Suspected rhabdomyolysis (e.g., markedly elevated AST with elevated CPK).&#xD;
&#xD;
             Known or suspected autoimmune hepatitis.&#xD;
&#xD;
             Known or suspected biliary diseases, such as primary biliary cirrhosis or sclerosing&#xD;
             cholangitis.&#xD;
&#xD;
             Known or suspected Wilson's disease, alpha-1-antitrypsin deficiency, celiac disease.&#xD;
&#xD;
             History of primary hemochromatosis, glycogen storage disease, amyloidosis, or cystic&#xD;
             fibrosis.&#xD;
&#xD;
             Clinical evidence of decompensated liver disease (e.g., jaundice, ascites, esophageal&#xD;
             varices, or hepatic encephalopathy).&#xD;
&#xD;
             Active clinical pancreatitis.&#xD;
&#xD;
             Chronic renal disease.&#xD;
&#xD;
             Morbid obesity (BMI greater than or equal to 40), if judged to be a contradiction to&#xD;
             percutaneous liver biopsy&#xD;
&#xD;
             AFP greater than or equal to 100 ng/mL.&#xD;
&#xD;
             Hepatoma or hepatocellular carcinoma.&#xD;
&#xD;
             Pregnancy.&#xD;
&#xD;
             Active opportunistic infection (except oral thrush) or neoplasm (except Kaposi's&#xD;
             sarcoma, skin cancer, or cancer of the cervix or anus, unless known or suspected liver&#xD;
             metastasis).&#xD;
&#xD;
             Severe psychiatric disorder that would interfere with adherence to protocol&#xD;
             requirements. Individuals who have a stable psychiatric condition may be eligible.&#xD;
&#xD;
             Decompensated cardiac or pulmonary disease limiting physical activity (e.g., New York&#xD;
             Heart Association Heart Failure Class 2 or higher).&#xD;
&#xD;
             History of unexplained bleeding.&#xD;
&#xD;
             Allergy to lidocaine.&#xD;
&#xD;
             Current use or a history of treatment with interleukin-2, interferon-alpha or other&#xD;
             investigational agent(s) within 6 months of protocol screening. However,&#xD;
             antiretroviral medication obtained through expanded access programs are permitted.&#xD;
&#xD;
             Current use or a history of treatment with a systemic corticosteroid,&#xD;
             immunosuppressive or cytotoxic agent within 90 days of protocol screening. However,&#xD;
             volunteers receiving no more than one day of corticosteroid therapy in the 90 days&#xD;
             prior to screening will be eligible.&#xD;
&#xD;
             Any medical condition for which an investigator believes liver biopsy may be&#xD;
             contraindicated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janaki C Kuruppu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health Clinical Center (CC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2006-I-0153.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000 Jan 5;283(1):74-80.</citation>
    <PMID>10632283</PMID>
  </reference>
  <reference>
    <citation>Crum-Cianflone N, Collins G, Medina S, Asher D, Campin R, Bavaro M, Hale B, Hames C. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons. Clin Gastroenterol Hepatol. 2010 Feb;8(2):183-91. doi: 10.1016/j.cgh.2009.09.025. Epub 2009 Oct 2.</citation>
    <PMID>19800985</PMID>
  </reference>
  <reference>
    <citation>Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, Charlotte F, Tubiana R, Poynard T, Katlama C, Lomb√®s A, Benhamou Y. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology. 2009 Feb;49(2):436-42. doi: 10.1002/hep.22665.</citation>
    <PMID>19085967</PMID>
  </reference>
  <verification_date>October 22, 2021</verification_date>
  <study_first_submitted>May 16, 2006</study_first_submitted>
  <study_first_submitted_qc>May 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2006</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Toxicity</keyword>
  <keyword>Steatohepatitis</keyword>
  <keyword>Hepatotoxicity</keyword>
  <keyword>Liver Biopsy</keyword>
  <keyword>Liver Disease</keyword>
  <keyword>HIV</keyword>
  <keyword>Liver Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

